Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock

Biochemical and Biophysical Research Communications

Volumn 458, Issue 3, 2015, Pages 667-673

  Shi Lin, Du ^a   Yuan, Xue ^a   Zhan, Sun ^a   Luo Jia, Tang ^a   Chao Yang, Tong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b No 180 Fenglin Road ^*  (China)

Author keywords

Lipopolysaccharide (LPS); MEK ERK signaling and endotoxin shock; Trametinib; Tumor necrosis factor (TNF)

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; SHORT HAIRPIN RNA; TRAMETINIB; TUMOR NECROSIS FACTOR ALPHA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; HUMAN; HUMAN CELL; LENTIVIRINAE; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; SEPTIC SHOCK; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CELL LINE; DRUG EFFECTS; IMMUNOLOGY; MALE; MONONUCLEAR CELL; SHOCK, SEPTIC; YOUNG ADULT;

LENTIVIRUS; MURINAE; MUS;

ADULT; ANIMALS; CELL LINE; CELLS, CULTURED; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTEIN KINASE INHIBITORS; PYRIDONES; PYRIMIDINONES; SHOCK, SEPTIC; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84924049107     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.01.160     Document Type: Article

References (28)

1. E. Nikoopour, J.A. Schwartz, and B. Singh Therapeutic benefits of regulating inflammation in autoimmunity Inflammation Allergy Drug Targets 7 2008 203 210
2. M. Karin, and F.R. Greten NF-kappaB: linking inflammation and immunity to cancer development and progression Nat. Rev. Immunol. 5 2005 749 759
3. C. Nathan Points of control in inflammation Nature 420 2002 846 852
4. J. Vakkila, and M.T. Lotze Inflammation and necrosis promote tumour growth Nat. Rev. Immunol. 4 2004 641 648
5. S. Mariathasan, and D.M. Monack Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation Nat. Rev. Immunol. 7 2007 31 40
6. S.I. Miller, R.K. Ernst, and M.W. Bader LPS, TLR4 and infectious disease diversity Nat. Rev. Microbiol. 3 2005 36 46
7. A. Aderem, and R.J. Ulevitch Toll-like receptors in the induction of the innate immune response Nature 406 2000 782 787
8. Z. Jiang, P. Georgel, X. Du, L. Shamel, S. Sovath, S. Mudd, M. Huber, C. Kalis, S. Keck, C. Galanos, M. Freudenberg, and B. Beutler CD14 is required for MyD88-independent LPS signaling Nat. Immunol. 6 2005 565 570
9. T. Reimann, D. Buscher, R.A. Hipskind, S. Krautwald, M.L. Lohmann-Matthes, and M. Baccarini Lipopolysaccharide induces activation of the Raf-1/MAP kinase pathway. A putative role for Raf-1 in the induction of the IL-1 beta and the TNF-alpha genes J. Immunol. 153 1994 5740 5749
10. T.D. Geppert, C.E. Whitehurst, P. Thompson, and B. Beutler Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway Mol. Med. 1 1994 93 103
11. C.D. Dumitru, J.D. Ceci, C. Tsatsanis, D. Kontoyiannis, K. Stamatakis, J.H. Lin, C. Patriotis, N.A. Jenkins, N.G. Copeland, G. Kollias, and P.N. Tsichlis TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway Cell 103 2000 1071 1083
12. G.S. Falchook, K.D. Lewis, J.R. Infante, M.S. Gordon, N.J. Vogelzang, D.J. DeMarini, P. Sun, C. Moy, S.A. Szabo, L.T. Roadcap, V.G. Peddareddigari, P.F. Lebowitz, N.T. Le, H.A. Burris 3rd, W.A. Messersmith, P.J. O'Dwyer, K.B. Kim, K. Flaherty, J.C. Bendell, R. Gonzalez, R. Kurzrock, and L.A. Fecher Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial Lancet Oncol. 13 2012 782 789
13. J.R. Infante, L.A. Fecher, G.S. Falchook, S. Nallapareddy, M.S. Gordon, C. Becerra, D.J. DeMarini, D.S. Cox, Y. Xu, S.R. Morris, V.G. Peddareddigari, N.T. Le, L. Hart, J.C. Bendell, G. Eckhardt, R. Kurzrock, K. Flaherty, H.A. Burris 3rd, and W.A. Messersmith Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial Lancet Oncol. 13 2012 773 781
14. K.T. Flaherty, C. Robert, P. Hersey, P. Nathan, C. Garbe, M. Milhem, L.V. Demidov, J.C. Hassel, P. Rutkowski, P. Mohr, R. Dummer, U. Trefzer, J.M. Larkin, J. Utikal, B. Dreno, M. Nyakas, M.R. Middleton, J.C. Becker, M. Casey, L.J. Sherman, F.S. Wu, D. Ouellet, A.M. Martin, K. Patel, and D. Schadendorf Improved survival with MEK inhibition in BRAF-mutated melanoma N. Engl. J. Med. 367 2012 107 114
15. M. Watanabe, Y. Sowa, M. Yogosawa, and T. Sakai Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells Cancer Sci. 104 2013 687 693
16. K.B. Dahlman, J. Xia, K. Hutchinson, C. Ng, D. Hucks, P. Jia, M. Atefi, Z. Su, S. Branch, P.L. Lyle, D.J. Hicks, V. Bozon, J.A. Glaspy, N. Rosen, D.B. Solit, J.L. Netterville, C.L. Vnencak-Jones, J.A. Sosman, A. Ribas, Z. Zhao, and W. Pao BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors Cancer Discovery 2 2012 791 797
17. J. Shen, L. Liang, and C. Wang Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment Biochem. Biophys. Res. Commun. 437 2013 250 255
18. J.L. Zhang, Y. Xu, and J. Shen Cordycepin inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-alpha production via activating amp-activated protein kinase (AMPK) signaling Int. J. Mol. Sci. 15 2014 12119 12134
19. K.J. Livak, and T.D. Schmittgen Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method Methods 25 2001 402 408
20. J. Wang, M.W. Whiteman, H. Lian, G. Wang, A. Singh, D. Huang, and T. Denmark A non-canonical MEK/ERK signaling pathway regulates autophagy via regulating Beclin 1 J. Biol. Chem. 284 2009 21412 21424
21. D.M. Walters, J.M. Lindberg, S.J. Adair, T.E. Newhook, C.R. Cowan, J.B. Stokes, C.A. Borgman, E.B. Stelow, B.T. Lowrey, M.E. Chopivsky, T.M. Gilmer, J.T. Parsons, and T.W. Bauer Inhibition of the growth of patient-derived pancreatic cancer xenografts with the MEK inhibitor trametinib is augmented by combined treatment with the epidermal growth factor receptor/HER2 inhibitor lapatinib Neoplasia 15 2013 143 155
22. Q. Li, and I.M. Verma NF-kappaB regulation in the immune system Nat. Rev. Immunol. 2 2002 725 734
23. Y. Bordon Inflammation: TNF snuffs out steroids Nat. Rev. Immunol. 14 2014 214
24. E. Jirillo, D. Caccavo, T. Magrone, E. Piccigallo, L. Amati, A. Lembo, C. Kalis, and M. Gumenscheimer The role of the liver in the response to LPS: experimental and clinical findings J. Endotoxin Res. 8 2002 319 327
25. T.K. Means, R.P. Pavlovich, D. Roca, M.W. Vermeulen, and M.J. Fenton Activation of TNF-alpha transcription utilizes distinct MAP kinase pathways in different macrophage populations J. Leukoc. Biol. 67 2000 885 893
26. E.Y. Tsai, J.V. Falvo, A.V. Tsytsykova, A.K. Barczak, A.M. Reimold, L.H. Glimcher, M.J. Fenton, D.C. Gordon, I.F. Dunn, and A.E. Goldfeld A lipopolysaccharide-specific enhancer complex involving Ets, Elk-1, Sp1, and CREB binding protein and p300 is recruited to the tumor necrosis factor alpha promoter in vivo Mol. Cell. Biol. 20 2000 6084 6094
27. M.K. Cho, Y.P. Jang, Y.C. Kim, and S.G. Kim Arctigenin, a phenylpropanoid dibenzylbutyrolactone lignan, inhibits MAP kinases and AP-1 activation via potent MKK inhibition: the role in TNF-alpha inhibition Int. Immunopharmacol. 4 2004 1419 1429
28. A.M. Grimaldi, E. Simeone, and P.A. Ascierto The role of MEK inhibitors in the treatment of metastatic melanoma Curr. Opin. Oncol. 26 2014 196 203